Research News 2
Research News
-
On the Same Page?
Researchers, including amfAR grantee Dr. Rachel Rutishauser, seek to gain insights by harmonizing definitions and conclusions across HIV cure trials.
-
The “French Patient” May Be the Latest Person Cured of HIV
Known as the “French Patient,” a woman who received a stem cell transplant with donor cells without intact CCR5 receptors is likely the latest HIV cure case.
-
Unmasking the Power of the Pediatric Immune System
In a new study, researchers examine the impact of long-term antiretroviral therapy started during infancy on the HIV reservoir.
-
The Second Berlin Patient
The second Berlin Patient HIV cure opens up new possibilities and amfAR researchers are working to make this strategy an accessible, affordable one.
-
Six Researchers, One Goal
New amfAR grants totaling more than $2.5 million support strategies to cure HIV, from immunotherapy to latency-reversing and anti-cancer agents.
-
Inhibiting HIV by Host Cell Targeting Strategies
-
Beyond Stem Cell Transplantation?
amfAR awards grants to researchers—Drs. Jonah Sacha, Elena Herrera-Carrillo, and Alexander Pasternak—who are testing innovative HIV cure strategies.
-
Predicting Changes in the HIV Reservoir
Researchers zero in on a marker, sugar-protein Galectin-9, that might be able to target HIV persistence, the main barrier to a cure for people living with the virus.
-
A Possible New Avenue to a Cure
A study of the Geneva patient, cured of HIV via a transplant with cells susceptible to infection, opens up new possibilities of eradicating the virus.
-
Lenacapavir Looks to Revolutionize HIV Prevention
PURPOSE 2 study results show that a twice-yearly injectable HIV antiretroviral, lenacapavir, is highly effective as PrEP among MSM, transgender women and men who have sex with men, and others.
-
Researchers Identify a Novel Cell Protein that Can Control HIV Growth
Researchers have discovered a cell protein that can restrict the late phases of HIV replication as well as that of pox viruses.
-
Next-Generation PrEP
PURPOSE 1 trial results show that a twice-yearly injectable—lenacapavir for PrEP—is 100% effective at preventing HIV infection among cisgender women and girls.
-
Daily Updates from the 2024 International AIDS Conference
Daily updates of sessions at AIDS 2024 cover research on curing HIV, HIV care, and AIDS policy from amfAR and others.
-
The Second Berlin Patient
A seventh person, the second Berlin Patient, has been cured of HIV, providing new evidence that a stem cell transplant with a CCR5 gene mutation might not be the only path to a cure.
-
amfAR Greenlights New HIV Cure Studies with Grants Totaling $1.2 Million
amfAR grants totaling $1.2 million allow three researchers to test the ability of a pair of cancer drugs and broadly neutralizing antibodies to attack HIV reservoirs, the main barrier to a cure.